Klosterfrau Invests €60M in Berlin: 50M Syringes Per Year

Klosterfrau Healthcare Group is making a substantial investment in its Berlin operations, committing €60 million over four years to expand and modernize its production facilities. According to an article in apotheke adhoc, the investment will focus on creating state-of-the-art manufacturing capabilities, with sustainability as a key component.

The first phase of this ambitious project has already been completed with the opening of a new facility for sterile prefilled syringes. This 1,200 square meter clean room facility represents a €25 million investment and will be capable of producing up to 50 million syringes per year. The majority of these products will be distributed internationally by Klosterfrau's subsidiary Farco-Pharma in Cologne, Germany.

During the opening ceremony last Friday, CEO Dr. Stefan Koch emphasized the company's commitment to combining state-of-the-art manufacturing technology with innovative energy concepts in Germany. "We are confident that these investments will further strengthen the Berlin site," said Koch.

Christoph Klaus, Managing Director, explained that the decision to expand in Berlin rather than move production abroad was a conscious one. "We made a clear decision for the German location," he said, noting that technical service can be guaranteed in Germany within a very short time, which would be more difficult from abroad.

Klosterfrau currently operates three plants in Berlin, producing sterile pre-filled syringes such as Instillagel, liquid medications such as Melissengeist or Nasic, and medical lozenges such as Neo-Angin. The company plans to continue its modernization with the opening of a new facility for medical lozenges in two years.